These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 38132459)

  • 21. Dl-3-n-Butylphthalide Alleviates Behavioral and Cognitive Symptoms Via Modulating Mitochondrial Dynamics in the A53T-α-Synuclein Mouse Model of Parkinson's Disease.
    Li H; Wang H; Zhang L; Wang M; Li Y
    Front Neurosci; 2021; 15():647266. PubMed ID: 34121985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.
    Wills J; Credle J; Haggerty T; Lee JH; Oaks AW; Sidhu A
    PLoS One; 2011 Mar; 6(3):e17953. PubMed ID: 21445308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender Differences in Neurodegeneration, Neuroinflammation and Na
    Costa G; Sisalli MJ; Simola N; Della Notte S; Casu MA; Serra M; Pinna A; Feliciello A; Annunziato L; Scorziello A; Morelli M
    Front Aging Neurosci; 2020; 12():118. PubMed ID: 32477098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
    Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
    Park JS; Choe K; Lee HJ; Park TJ; Kim MO
    J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of Adult Neurogenesis by Intranasal Administration of Gangliosides GD3 and GM1 in The Olfactory Bulb of A53T Alpha-Synuclein-Expressing Parkinson's-Disease Model Mice.
    Fuchigami T; Itokazu Y; Morgan JC; Yu RK
    Mol Neurobiol; 2023 Jun; 60(6):3329-3344. PubMed ID: 36849668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.
    George S; Mok SS; Nurjono M; Ayton S; Finkelstein DI; Masters CL; Li QX; Culvenor JG
    J Mol Neurosci; 2010 Oct; 42(2):243-54. PubMed ID: 20464527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA damage preceding dopamine neuron degeneration in A53T human α-synuclein transgenic mice.
    Wang D; Yu T; Liu Y; Yan J; Guo Y; Jing Y; Yang X; Song Y; Tian Y
    Biochem Biophys Res Commun; 2016 Dec; 481(1-2):104-110. PubMed ID: 27818201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice.
    Parrella E; Bellucci A; Porrini V; Benarese M; Lanzillotta A; Faustini G; Longhena F; Abate G; Uberti D; Pizzi M
    Transl Neurodegener; 2019; 8():16. PubMed ID: 31139367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
    Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
    J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.
    Niu Y; Guo X; Chen Y; Wang CE; Gao J; Yang W; Kang Y; Si W; Wang H; Yang SH; Li S; Ji W; Li XJ
    Hum Mol Genet; 2015 Apr; 24(8):2308-17. PubMed ID: 25552648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
    Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
    Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
    Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A
    PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.